Pliant Therapeutics Presentations At The Annual Meeting Of The Society For Immunotherapy Of Cancer Highlight PLN-101095, A Novel Inhibitor Of Integrins αvβ8 And αvβ1
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics, Inc. (NASDAQ:PLRX) presented three posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, highlighting PLN-101095, a novel inhibitor of integrins αvβ8 and αvβ1. The company is conducting a Phase 1a trial of PLN-101095 as monotherapy and in combination with pembrolizumab in treatment-resistant patients with advanced or metastatic solid tumors. The inhibitor was also shown to decrease primary tumor growth and improve chemosensitivity in preclinical models of pancreatic ductal adenocarcinoma.
November 06, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics is conducting a Phase 1a trial of PLN-101095, a novel inhibitor, in treatment-resistant patients with advanced or metastatic solid tumors. The inhibitor has shown promising results in preclinical models.
The news about the ongoing Phase 1a trial and the promising results from preclinical models could potentially increase investor confidence in Pliant Therapeutics, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100